Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Gastrointestinal Stromal Tumors 26Leukemia 20Leukemia, Myeloid, Chronic-Phase 15Philadelphia Chromosome 9Leukemia, Myeloid 8Bone Marrow Diseases 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Hematologic Neoplasms 4Hematologic Diseases 4Blast Crisis 4Myeloproliferative Disorders 3Leukemia, Myeloid, Acute 3Hypereosinophilic Syndrome 3Glioblastoma 3Digestive System Neoplasms 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Prostatic Neoplasms 2Neurofibrosarcoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Accelerated Phase 2Dermatofibrosarcoma 2Chordoma 2Brain Neoplasms 2Adenocarcinoma 2Urogenital Neoplasms 1

Interventions

masitinib 2nilotinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Piebaldism × Imatinib Mesylate × Clear all
NCT00237185 2014-08-19

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Novartis

Phase 2 Completed
148 enrolled 17 charts
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡